Chemoinformaics analysis of TRANS-3-CAREN-2-OL
| Molecular Weight | 152.237 | nRot | 0 |
| Heavy Atom Molecular Weight | 136.109 | nRig | 8 |
| Exact Molecular Weight | 152.12 | nRing | 2 |
| Solubility: LogS | -2.59 | nHRing | 0 |
| Solubility: LogP | 2.801 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 27 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 28.1707 |
| nHD | 1 | BPOL | 16.0513 |
| QED | 0.526 |
| Synth | 4.038 |
| Natural Product Likeliness | 3.212 |
| NR-PPAR-gamma | 0.002 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.007 |
| HIA | 0.009 |
| CACO-2 | -4.326 |
| MDCK | 0.0000244 |
| BBB | 0.958 |
| PPB | 0.774485 |
| VDSS | 1.214 |
| FU | 0.274186 |
| CYP1A2-inh | 0.122 |
| CYP1A2-sub | 0.379 |
| CYP2c19-inh | 0.036 |
| CYP2c19-sub | 0.799 |
| CYP2c9-inh | 0.044 |
| CYP2c9-sub | 0.832 |
| CYP2d6-inh | 0.007 |
| CYP2d6-sub | 0.636 |
| CYP3a4-inh | 0.018 |
| CYP3a4-sub | 0.234 |
| CL | 14.523 |
| T12 | 0.179 |
| hERG | 0.013 |
| Ames | 0.004 |
| ROA | 0.15 |
| SkinSen | 0.115 |
| Carcinogencity | 0.08 |
| EI | 0.479 |
| Respiratory | 0.714 |
| NR-Aromatase | 0.004 |
| Antiviral | No |
| Prediction | 0.941852 |